CN1310645C - Bacteriostasis antiinflammation pain-stopping pharmaceutical composition and application thereof - Google Patents
Bacteriostasis antiinflammation pain-stopping pharmaceutical composition and application thereof Download PDFInfo
- Publication number
- CN1310645C CN1310645C CNB2005100940605A CN200510094060A CN1310645C CN 1310645 C CN1310645 C CN 1310645C CN B2005100940605 A CNB2005100940605 A CN B2005100940605A CN 200510094060 A CN200510094060 A CN 200510094060A CN 1310645 C CN1310645 C CN 1310645C
- Authority
- CN
- China
- Prior art keywords
- matrine
- inflammation
- pharmaceutical composition
- borneolum syntheticum
- bacteriostasis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a medicinal composition for inhibiting bacterium, relieving inflammation and stopping pain, which is characterized in that the composition is composed of matrine and borneol, wherein the weight ratio of the matrine to the borneol is 1: 0.04 to 10, and the optimal weight ratio of the matrine to the borneol is 1: 0.1 to 4. Pharmacodynamics tests indicate that the composition has obvious effects of inhibiting the bacterium, relieving the inflammation and stopping the pain. The medicine composition can be made into medicines for treating gynecopathies, such as vaginitis, pelvic inflammation, cervicitis, cervical erosion, etc.
Description
Technical field:
The present invention is a kind of pharmaceutical composition of being made up of matrine and Borneolum Syntheticum.The said composition tool is antibacterial significantly, antiinflammatory and analgesic effect, can be used for making the medicine of gynaecological inflammation diseases such as treatment vaginitis, pelvic inflammatory disease, cervicitis and cervical erosion.
Background technology:
Gynecological inflammation is women's a commonly encountered diseases, and acute and chronic inflammation can take place women's multiple organ, and in the environment of our life, common gynecologic inflammation mainly contains female vulva inflammation, vaginitis, cervicitis and pelvic inflammatory disease.
Gynecological inflammation sickness rate height, according to the inflammation expert introduction,, 80% adult women will suffer from gynecological inflammation in life one to twice, wherein the most commonly vaginitis and cervical disease.All kinds of gynecological inflammations such as vaginitis, cervicitis, cervical erosion and even pelvic inflammatory disease are " beauty killers ".
The Western medicine of treatment gynecological inflammation mostly is antibiotic, the normal phase uses and can produce drug resistance, some antibiotic also has gastrointestinal side effect, lesions of liver and kidney and skin irritation, is unfavorable for the long-term prescription of gynecological inflammation, and Chinese patent medicine plays an important role aspect sick in that treatment gynecological is scorching.On the gynecological Chinese patent medicine markets in 2002, be 57.75% the market share that representative treatment gynecological inflammation medicine has occupied Amino-Cerv with FUKE QIANJIN PIAN, Dianthus carryophyllus KANGGONGYAN PIAN.
It is clear and definite to develop a kind of effective ingredient, quality controllable, determined curative effect, the little gynecological inflammation of side effect medical instrument significance.
Summary of the invention:
The objective of the invention is to develop a kind of prescription and simplify, effective ingredient is clear and definite, determined curative effect, quality controllable and bacteriostasis antiinflammation pain-stopping pharmaceutical composition that side effect is low.
Another object of the present invention is to this pharmaceutical composition and can be used for preparing the application for the treatment of in the gynecological inflammation medicine, especially can be used for preparing the application in treatment vaginitis, pelvic inflammatory disease, cervicitis and the cervical erosion medicine.
A kind of bacteriostasis antiinflammation pain-stopping pharmaceutical composition is characterized in that said composition is made up of matrine and Borneolum Syntheticum, and its weight ratio is 1: 0.04～10; Its optimum weight ratio is 1: 0.1～4.
Prescription foundation of the present invention: matrine is an isolated monosomic alkali from the plant Herba Sophorae alopecuroidis.Have effects such as antibiotic, antiinflammatory, diuresis, leukocyte increasing, confirm that through pharmaceutical research matrine can improve rotten to the corn face blood circulation, strengthen the phagocyte phagocytic function, pathogenic microbe killing; Simultaneously, but granulation promoting, restrain, make rotten to the corn face simple columnar epithelium necrocytosis to come off, cover, and cure rapidly by newborn pavement epithelium cells.Borneolum Syntheticum tool have one's ideas straightened out refreshment, reducing swelling and alleviating pain, removing the necrotic tissue and promoting granulation, blood-cooling itch-relieving, refrigerant effect such as comfortable.Two medicines share, and effect is collaborative, complementary, antibiotic, the antiinflammatory that tool is good, the effect of pain relieving, and its prescription simplifies, and effective ingredient is clear and definite, the deficiency of complementary single medicinal material.
Antibiotic, the antiinflammatory that tool of the present invention is good, the effect of pain relieving can be used for making the medicine of gynaecological inflammation diseases such as treatment vaginitis, pelvic inflammatory disease, cervicitis and cervical erosion.
Pharmacodynamic study is as follows:
1, external bacteriostatic experiment
Examined or check the bacteriostasis of this product to the common clinical pathogenic bacteria of gynecological inflammation.
Method:
Must to clinical bacterium staphylococcus aureus, escherichia coli, staphylococcus epidermidis, Hemolytic streptococcus strain be transferred in the corresponding slant medium, 37 ℃ leave standstill cultivation 12 hours.Corresponding strain is transferred in the fluid medium shaken cultivation (37 ℃, 190 rev/mins) 12 hours.Corresponding bacterium liquid is transferred in the multiple spot inoculation instrument, multiple spot inoculation in the LB of dosing flat board or blood plate, 37 ℃ leave standstill cultivation 12 hours.Simultaneously with the plating bacterium of not dosing as positive control, do not inoculate bacterium as negative control with the flat board of not dosing.If do not occur suppressing fully, concentration is progressively risen, up to inhibition fully occurring.Observed result, with the not long bacterium of feminine gender, positive control has bacteria growing to test effective standard as this.Bacterium colony is arranged as the invalid standard of medicine with inoculation point, asepticly fall to being grown to medicine and suppress effectively.With to the minimum inhibitory concentration (MIC) of certain concentration of all suppressing of all bacterial strains of series as this antibacterial.
The results are shown in Table 1, table 2:
Table 1: to the antibacterial result of the common clinical pathogenic bacteria of gynecological inflammation
| Drug level (g/ml) | Staphylococcus aureus | Escherichia coli | Staphylococcus epidermidis | Hemolytic streptococcus |
| 0.043 | 0/4 | 0/3 | 0/4 | 0/1 |
| 0.032 | 0/4 | 0/3 | 1/3 | 0/1 |
| 0.016 | 0/4 | 1/2 | 1/3 | 0/1 |
| 0.008 | 2/2 | 1/2 | 1/3 | 0/1 |
| 0.004 | 4/0 | 3/0 | 4/0 | 1/0 |
| 0.002 | 4/0 | 3/0 | 4/0 | 1/0 |
| 0.001 | 4/0 | 3/0 | 4/0 | 1/0 |
Annotate: represent that with N1/N2 N1 represents to have the bacterial strain of bacteria growing, N2 represents not have the bacterial strain (0/4 is inhibition fully, and 4/0 expression does not suppress fully) of bacteria growing
Table 2: to the minimum inhibitory concentration (MIC) of the common clinical pathogenic bacteria of gynecological inflammation
| Staphylococcus aureus | Escherichia coli | Staphylococcus epidermidis | Hemolytic streptococcus | |
| MIC(g/ml) | 0.0 16 | 0.032 | 0.043 | 0.008 |
Experimental result shows, this compositions is to the common clinical pathogenic bacteria tool of gynecological inflammation bacteriostasis preferably.
2, suppress the scorching experiment of Mice Auricle caused by dimethylbenzene xylene
Select 30 of Kunming kind white mice for use, weigh, be divided into 3 groups (n=10) at random, the male and female dual-purpose is respectively the substrate matched group, pharmaceutical composition group and urea cream positive controls.The 0.1g medicine is applied to each corresponding group mice left side ear tow sides, and auris dextra drips xylene solution 30 μ l with the left ear tow sides of mice behind the 45min and causes inflammation in contrast.15min post-tensioning neck is put to death animal, the mice ears is downcut scales/electronic balance weighing with the 8mm card punch with the position homalographic.Subtracting auris dextra weight with left ear preparation weight is the swelling degree.Obtain inhibitory rate of intumesce (%) by following formula:
Inhibitory rate of intumesce (%)=(the average swelling degree of the matrix group-average swelling degree of administration group) * average swelling degree of 100%/matrix group
Result's (seeing Table 3) shows that this pharmaceutical composition has significant antiinflammatory action.
The influence (n=10) of table 3 xylol induced mice auricle edema
| Group | Swelling degree (mg) X ± SD | Inhibitory rate of intumesce (%) |
| The matrix group sun is to group compositions group | 15.2±4.2 9.7±3.8** 11.1±4.2* | 36.1 26.9 |
Annotate: * p＜0.05, compare with matrix group * * p＜0.01
3, mice analgesic experiment
Kunming mouse, ♀ ♂ half and half, 18-21g, 30, be divided into 3 groups at random, 10 every group, be respectively blank group, aspirin group (positive controls) and pharmaceutical composition group, behind the administration 30min, the acetic acid 0.1ml/10g of the equal ip of each treated animal injection 0.6% observes mouse writhing number of times in back 15 minutes of injection.Carry out the analysis of t inspection statistics by administration group and blank group.
Result's (seeing Table 4) shows the significant analgesic activity of this pharmaceutical composition tool.
Table 4: the inhibitory action that mice acetic acid is caused pain reaction (is turned round the body number, n=10, x ± s)
| Group | Dosage | Turn round the body number |
| Blank group aspirin group compositions group | 0.2ml/kg 200mg/kg 100mg/kg | 29.2±4.9 8.1±3.6** 10.2±4.1** |
Annotate: * * p＜0.01, compare with the blank group
Above-mentioned 3 experiments show, this pharmaceutical composition is not only to the common clinical pathogenic bacteria tool of gynecological inflammation bacteriostasis preferably, and the significant antiinflammatory of tool, analgesic effect illustrate this product when resisting the gynecological inflammation pathogenic bacterium, to the also tool auxiliary treatment effect preferably of inflammation, pain symptom.
The specific embodiment:
Embodiment 1:
The drug combination preparation of matrine and Borneolum Syntheticum: get matrine 30g, Borneolum Syntheticum 300g, add an amount of dissolving of ethanol and mix homogeneously.Other gets glycerin gelatine 1170g and puts in the water-bath and melt, and adds above-mentioned medicinal liquid, fully stirs evenly, and pours in the suppository mold, and take out the cooling back, makes 1000, promptly.
Embodiment 2:
The drug combination preparation of matrine and Borneolum Syntheticum: get matrine 50g, Borneolum Syntheticum 200g, add an amount of dissolving of ethanol and mix homogeneously.Other gets glycerin gelatine 1250g and puts in the water-bath and melt, and adds above-mentioned medicinal liquid, fully stirs evenly, and pours in the suppository mold, and take out the cooling back, makes 1000, promptly.
Embodiment 3:
The drug combination preparation of matrine and Borneolum Syntheticum: get matrine 50g, Borneolum Syntheticum 100g, add an amount of dissolving of ethanol and mix homogeneously.Other gets glycerin gelatine 1350g and puts in the water-bath and melt, and adds above-mentioned medicinal liquid, fully stirs evenly, and pours in the suppository mold, and take out the cooling back, makes 1000, promptly.
Embodiment 4:
The drug combination preparation of matrine and Borneolum Syntheticum: get matrine 50g, Borneolum Syntheticum 75g, add an amount of dissolving of ethanol and mix homogeneously.Other gets glycerin gelatine 1375g and puts in the water-bath and melt, and adds above-mentioned medicinal liquid, fully stirs evenly, and pours in the suppository mold, and take out the cooling back, makes 1000, promptly.
Embodiment 5:
The preparation of matrine and Borneolum Syntheticum: get matrine 50g, Borneolum Syntheticum 50g, add an amount of dissolving of ethanol and mix homogeneously.Other gets glycerin gelatine 1400g and puts in the water-bath and melt, and adds above-mentioned medicinal liquid, fully stirs evenly, and pours in the suppository mold, and take out the cooling back, makes 1000, promptly.
Embodiment 6:
The drug combination preparation of matrine and Borneolum Syntheticum: get matrine 50g, Borneolum Syntheticum 40g, add an amount of dissolving of ethanol and mix homogeneously.Other gets glycerin gelatine 1410g and puts in the water-bath and melt, and adds above-mentioned medicinal liquid, fully stirs evenly, and pours in the suppository mold, and take out the cooling back, makes 1000, promptly.
Embodiment 7:
The drug combination preparation of matrine and Borneolum Syntheticum: get matrine 50g, Borneolum Syntheticum 20g, add an amount of dissolving of ethanol and mix homogeneously.Other gets glycerin gelatine 1430g and puts in the water-bath and melt, and adds above-mentioned medicinal liquid, fully stirs evenly, and pours in the suppository mold, and take out the cooling back, makes 1000, promptly.
Embodiment 8:
The drug combination preparation of matrine and Borneolum Syntheticum: get matrine 50g, Borneolum Syntheticum 5g, add an amount of dissolving of ethanol and mix homogeneously.Other gets glycerin gelatine 1445g and puts in the water-bath and melt, and adds above-mentioned medicinal liquid, fully stirs evenly, and pours in the suppository mold, and take out the cooling back, makes 1000, promptly.
Embodiment 9:
The drug combination preparation of matrine and Borneolum Syntheticum: get matrine 50g, Borneolum Syntheticum 2g, add an amount of dissolving of ethanol and mix homogeneously.Other gets glycerin gelatine 1448g and puts in the water-bath and melt, and adds above-mentioned medicinal liquid, fully stirs evenly, and pours in the suppository mold, and take out the cooling back, makes 1000, promptly.
Claims (2)
1, a kind of bacteriostasis antiinflammation pain-stopping pharmaceutical composition is characterized in that said composition is made up of matrine and Borneolum Syntheticum, and its weight ratio is 1: 0.04～10.
2, bacteriostasis antiinflammation pain-stopping pharmaceutical composition according to claim 1 is characterized in that the weight ratio of matrine and Borneolum Syntheticum is 1: 0.1～4 in the said composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100940605A CN1310645C (en) | 2005-08-26 | 2005-08-26 | Bacteriostasis antiinflammation pain-stopping pharmaceutical composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100940605A CN1310645C (en) | 2005-08-26 | 2005-08-26 | Bacteriostasis antiinflammation pain-stopping pharmaceutical composition and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1732933A CN1732933A (en) | 2006-02-15 |
| CN1310645C true CN1310645C (en) | 2007-04-18 |
Family
ID=36075689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100940605A Expired - Fee Related CN1310645C (en) | 2005-08-26 | 2005-08-26 | Bacteriostasis antiinflammation pain-stopping pharmaceutical composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1310645C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108578466A (en) * | 2018-07-06 | 2018-09-28 | 兰州大学第医院 | A kind of ointment for treating beriberi and tinea pedis foot odour |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1334075A (en) * | 2001-05-30 | 2002-02-06 | 欧东波 | Flavescent sophora gargle and its preparing process |
-
2005
- 2005-08-26 CN CNB2005100940605A patent/CN1310645C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1334075A (en) * | 2001-05-30 | 2002-02-06 | 欧东波 | Flavescent sophora gargle and its preparing process |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1732933A (en) | 2006-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8765819B2 (en) | Composition comprising benzoic acid in combination with organic acid preservatives as active ingredients and the use thereof | |
| CN102160887A (en) | Medicament for treating gynecological inflammation and preparation method thereof | |
| CN102697784B (en) | Enrofloxacin injection for livestock and preparation method thereof | |
| CN109985069A (en) | Probiotic composition and application thereof | |
| EP3190893A1 (en) | Compositions and methods for treating and preventing bacterial infections | |
| CN105232526A (en) | Application of medicine containing catechin to preparation of antibacterial medicines | |
| CN101829130A (en) | Compound resveratrol anti-inflammatory and itching relieving medicament combination and purpose thereof | |
| CN1310645C (en) | Bacteriostasis antiinflammation pain-stopping pharmaceutical composition and application thereof | |
| CN104069124B (en) | Compositions and preparation for gynecological infection | |
| CN1173706C (en) | Application of N-acetyl-D-aminoglucose in preparing medicines to treat cervical erosion | |
| CN1799597A (en) | Application of Chinese medicinal composition in preparation of medicine for treating gynecological inflammation | |
| CN102824337A (en) | Compound chlorhexidine acetate gel for treating livestock endometritis, and preparation method thereof | |
| CN110227094B (en) | Application of albizia julibrissin aqueous extract in preparing external medicine for preventing and treating gynecological inflammatory diseases | |
| CN101623368A (en) | Drug for treating gynecological diseases and preparation technology thereof | |
| CN1850100A (en) | Medicinal composition for treating vagina disease | |
| CN111658763B (en) | Gynecological antibacterial gel and preparation method thereof | |
| CN100340263C (en) | Suppository for treating bacterial vaginitis | |
| CN1785204A (en) | Baicalin freeze-drying powder for injection use and its prepn. method | |
| US7704976B2 (en) | Use of N-acetyl-D-glucosamine for preparing medicines for urogenital tract infection's treatment and prevention | |
| CN1063632C (en) | External use liniment for curing dermatosis | |
| CN106580981B (en) | A kind of pharmaceutical composition and its preparation method and application for treating gynaecological imflammation | |
| CN106138124A (en) | The new purposes method of Flos abelmoschi manihot total flavones treatment gynaecopathia (vaginitis, cervicitis, cervical erosion) | |
| CN111388417B (en) | Breast injection containing cloxacillin benzathine and preparation method thereof | |
| DE102010032590B4 (en) | Medicines for the local treatment of wound infections | |
| CN1203868C (en) | External-use disinfecting medicinal preparation for women |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |